For patients with NSCLC with non-classical driver mutation alterations (atypical EGFR, BRAF nonV600E, etc), what resources do you utilize to determine likelihood that tumor will be sensitive to targeted therapies?   


Answer from: Medical Oncologist at Academic Institution